U.S. Chemicals Stock News

Comcast (CMCSA) has just opened 2026 reporting season with Q1 results that sit against a 2025 backdrop of quarterly revenue between US$30.3b and US$32.3b and basic EPS ranging from US$0.60 to US$2.99. Over the last six reported quarters, the company has seen revenue move between US$30.1b and US$32.1b while quarterly basic EPS tracked between roughly US$0.60 and US$2.99, feeding into trailing 12 month EPS of US$5.41 on US$123.7b of revenue. With a reported net margin of 16.2% over the last...

If you are wondering whether Parsons at around US$51.83 is starting to look like value or still pricing in a lot of optimism, the next sections will break that question down in plain terms. The stock has seen a 7.5% decline over the last week, a 2.8% gain over the past month, a 16.7% decline year to date, and a 23.0% decline over the last year, while still sitting on 3 year and 5 year returns of 19.0% and 15.5% respectively. These mixed returns have kept attention on how the market is...

If you are wondering whether Clean Harbors at around US$310 per share is still reasonably priced, the starting point is to understand how its current market value lines up with the underlying business. The stock has posted returns of 4.6% over the last 7 days, 8.8% over the past month, 27.5% year to date, 46.4% over 1 year, 115.1% over 3 years and 245.2% over 5 years. This naturally raises questions about how expectations and risk are being priced in today. Recent headlines have focused on...

Raymond James Financial (RJF) just posted its Q2 2026 scorecard, with revenue at US$3.7 billion and basic EPS of US$2.85 setting the tone for how the quarter landed on both the top and bottom line. The company has seen revenue move from US$3.4 billion in Q2 2025 to US$3.7 billion in Q2 2026, while basic EPS shifted from US$2.41 to US$2.85 over the same period. This provides a clear view of how sales and per share earnings are tracking year on year. Taken together, these numbers point to...

Why Amicus Therapeutics is on investors’ radar today Amicus Therapeutics (FOLD) has caught investor attention after recent performance data showed modest positive returns over the past month and past 3 months, prompting closer focus on how its rare disease portfolio supports the current valuation. See our latest analysis for Amicus Therapeutics. At a share price of $14.46, Amicus Therapeutics shows only modest short term share price returns. The 1 year total shareholder return of 100.83%...

Wondering if Choice Hotels International at around US$120 is offering good value today or if the easy money has already been made? This article walks through what the current price might actually be saying. The stock has recently shown mixed performance, with a 1.7% return over the last 7 days, 21.2% over 30 days and 24.9% year to date, set against a 3.9% decline over the past year and a 9.2% return over five years. Recent coverage has focused on how Choice Hotels International fits into the...

Essential Properties Realty Trust (EPRT) has kicked off Q1 2026 with total revenue of US$158.8 million, basic EPS of US$0.28 and net income of US$59.8 million, with management and investors also watching FFO of US$114.6 million and FFO per share of US$0.54 as key REIT metrics. Over the past year, the company has seen revenue move from US$129.4 million and basic EPS of US$0.30 in Q1 2025 to US$158.8 million and US$0.28 in the latest quarter, while trailing twelve month revenue reached US$590.7...

If you are wondering whether XP at around US$19.63 is still offering value or already pricing in the story, you are not alone. The stock has seen mixed moves recently, with a 7.1% decline over the past week, a 2.1% gain over 30 days, and returns of 21.3% year to date and 27.4% over the last year that may be reshaping how investors think about its risk and reward. Recent news coverage around XP has largely focused on its role in Brazil's capital markets and its position in the broader...

It's been a good week for Weatherford International plc ( NASDAQ:WFRD ) shareholders, because the company has just...

Wondering whether Ryan Specialty Holdings at US$35.40 is starting to look interesting on price, or if the recent weakness is a warning sign? This article breaks down what the current valuation is actually telling you. The stock has seen a 5.3% decline over the last 7 days, a 5.6% gain over the last 30 days, and returns of 30.1% decline year to date and 48.7% decline over the last year. This raises questions about how sentiment and risk are shifting around the name. Recent coverage has...

First American Financial (FAF) has followed up its earnings rebound with trailing 12‑month revenue of about US$7.5 billion and basic EPS of US$6.02, alongside year‑over‑year reported earnings growth of very roughly 4x and a net profit margin of 8.3% versus 2.1% a year earlier. The company has seen quarterly revenue move from US$1,406.1 million in Q3 2024 to US$1,685.1 million in Q4 2024 and then to US$2,049.7 million in Q4 2025, with basic EPS shifting from a loss of US$1.00 in Q3 2024 to...

Wondering if American Superconductor at around US$46.15 is still offering value or if the easy money has already been made? This article breaks down what the current price might really imply. The stock has seen sharp moves recently, with returns of 21.5% over 7 days, 43.3% over 30 days, 46.1% year to date and 129.3% over 1 year, along with a very large 3 year return that sits above 7x. These moves come as American Superconductor continues to attract attention from investors looking at power...

Kinder Morgan (KMI) opened 2026 with Q1 results that build on a solid recent run, with Q4 2025 revenue at US$4.5 billion and basic EPS of US$0.45 supported by net income of US$991 million. Over the past few quarters, revenue has moved from US$3.7 billion in Q3 2024 to US$4.0 billion in Q2 2025 and US$4.5 billion in Q4 2025, while basic EPS shifted from US$0.28 to US$0.32 and then to US$0.45. Together, these figures give you a clear sense of the recent earnings trajectory. With a trailing net...

If you are wondering whether Annaly Capital Management's share price still reflects fair value after a strong run, this article walks through what the current numbers may be saying about the stock. The stock last closed at US$22.43, with returns of 1.3% over 7 days, 6.4% over 30 days, a 2.1% decline year to date, 35.7% over 1 year, 70.0% over 3 years and 21.4% over 5 years. Recent coverage has focused on Annaly Capital Management's position within the mortgage REIT space and how interest...

Western Alliance Bancorporation (NYSE:WAL) addressed two significant fraud-related loan charge-offs in Q1 2026, which management believes helps clear legacy credit risk. The bank reported $5.6b in Q1 deposit growth and plans to shift from aggressive deposit gathering to a more balanced growth approach. These moves are intended to refine Western Alliance's risk management and funding profile following a period of strong deposit inflows. Western Alliance Bancorporation enters this shift with...

If you are wondering whether JD.com's current share price still offers value or if most of the opportunity is already priced in, this article breaks down what the market is paying for and what that might mean for you. The stock closed at US$29.98, with a 9.1% gain over 30 days, a 4.3% decline over 7 days, a 1.5% return year to date, and longer term returns of a 4.4% decline over 1 year, a 5.6% decline over 3 years, and a 56.2% decline over 5 years. Recent coverage around JD.com has focused...

Investors may be wondering whether Cytokinetics at around US$65.48 is still offering value, or if most of the upside is already reflected in the price. The stock has returned 0.1% over the last week, 9.1% over the past 30 days, 6.1% year to date and 62.4% over the last year, with longer term returns of 73.0% over 3 years and 148.1% over 5 years. Recent coverage has focused on Cytokinetics as a biotech name that investors are watching closely, with attention on how its pipeline and...

Investors may be asking whether Centene's current share price reflects its true worth, or if the recent weakness could be setting up a more interesting entry point. Centene's stock closed at US$41.09, with a 5.4% gain over the last 7 days and a 24.6% gain over the last 30 days, while returns sit at a 1.7% decline year to date and a 33.3% decline over the past year. Recent news around Centene has focused on its position in managed care and healthcare services, as investors weigh how policy,...

Corpay Cross-Border, part of NYSE:CPAY, has entered a new partnership with Toulouse Football Club as the club's Official FX Supplier. The agreement extends Corpay's reach in European football, following its previously announced relationship with AC Milan. The deal focuses on supporting Toulouse FC's international payment and currency risk management needs. For readers tracking NYSE:CPAY, this Toulouse FC partnership adds another high profile sports relationship to Corpay's cross border...

Goosehead Insurance (GSHD) has just posted its latest update for Q1 2026, with recent quarterly numbers showing Q4 2025 revenue of US$105.1 million and basic EPS of US$0.50 on net income of US$12.4 million. Over the past reported periods, revenue has moved from US$77.8 million in Q3 2024 to US$93.7 million in Q4 2024 and then to US$105.1 million in Q4 2025, while basic EPS over the same snapshot has been US$0.31, US$0.60 and US$0.50 respectively. This gives a clearer sense of how the top line...

Q1 2026 results set the tone for Roper Technologies (ROP) Roper Technologies (ROP) opened Q1 2026 earnings season with Q4 2025 revenue of US$2,058.6 million and basic EPS of US$4.00, backed by net income of US$428.4 million. Over the last few quarters, the company has seen revenue move from US$1,764.6 million in Q3 2024 to US$2,058.6 million in Q4 2025, while basic EPS shifted from US$3.43 to US$4.00. This gives investors a clearer view of how the top line and EPS are trending into the latest...

Immunome plans to present full Phase 3 RINGSIDE trial data for varegacestat in desmoid tumor patients at the 2026 ASCO Annual Meeting. The company expects to file a New Drug Application with the FDA for varegacestat after the ASCO presentation. The update highlights progress toward a potential new treatment option for this rare soft tissue tumor. For investors tracking Immunome, ticker NasdaqCM:IMNM, this update centers on a late stage program that could influence the company’s future...

If you are wondering whether Molson Coors Beverage is attractively priced at around US$42.87, the key is understanding what you are getting for that share price today. The stock has been under pressure over longer periods, with a 23.6% decline over the last year and a 9.6% drop year to date, although it has risen 4.2% over the past month while slipping 2.9% in the last week. Recent news flow around Molson Coors has focused on its position in the beverage sector and how investors are weighing...

Betterware de México, S.A.P.I. de C.V. reported past first-quarter 2026 results with sales of MX$3,509.7 million, slightly above the prior year’s MX$3,499.15 million, and net income of MX$281.34 million versus MX$151.39 million. The sharp improvement in profit despite broadly flat revenue suggests the company has recently become more efficient in converting sales into earnings. Next, we’ll examine how this stronger profitability trend could influence Betterware de México’s investment...